STAT+: Justice Department targets drugmakers in new directive on combating white-collar fraud
The Justice Department issued a new directive for combating fraud that noted the agency will pursue violations of a federal law that tightly regulates the pharmaceutical industry.
The U.S. Department of Justice recently released a new directive aimed at combating fraud in the pharmaceutical industry, according to the National Fraud Enforcement Division. This directive explicitly includes the Federal Food, Drug, and Cosmetic Act, signaling a shift in the agency's focus towards drug and device manufacturers.
Historically, the agency has primarily pursued health fraud cases involving providers, clinics, home health agencies, and hospices. Kevin Lowell, a former deputy chief in the National Fraud Enforcement Division's health care fraud section, noted that this expansion of the DOJ's jurisdiction is subtle yet significant.
Rewritten by urgent.news; may contain errors — check the original.